Neurocrine Biosciences, Inc., has announced the initiation of its Phase 1 clinical trial to evaluate NBI-1076986, a novel compound targeting the M4 subtype-selective muscarinic acetylcholine receptor. This trial, marking the first human assessment of the compound, aims to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants. NBI-1076986, developed internally by Neurocrine Biosciences, shows promise as a potential treatment for movement disorders such as Parkinson's disease tremor and dystonia.

Neurocrine Biosciences, stressed the importance of this compound within the company's muscarinic portfolio, highlighting its selective targeting of M4 receptors. This targeted approach holds potential therapeutic benefits across various motor coordination disorders.

The muscarinic receptor system is crucial for brain signaling pathways, with M4 receptors specifically implicated in motor coordination and certain central nervous system disorders. NBI-1076986, as a selective M4 subtype antagonist, aims to modulate motor symptoms while minimizing off-target effects, presenting a promising avenue for therapeutic intervention.

Neurocrine Biosciences also has a diverse pipeline of muscarinic receptor-targeting programs, including small molecule agonists for M1, M1/M4, and M4 receptors acquired from Nxera Pharma (formerly Sosei Heptares). These programs underscore the company's commitment to advancing novel treatments for neurological disorders.

 

Source: prnewswire.com

Report Abuse